Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis

2020334 citationsJournal Article

Authors

James D. Chalmers · Ninewells Hospital

Charles Haworth · University of Cambridge

Mark L. Metersky · University of Connecticut

Michael R. Loebinger · Imperial College London

Francesco Blasi · University of Milan

Oriol Sibila · Centro de Investigación Biomédica en Red de Enfermedades Respiratorias

Anne E. O’Donnell

Abstract

In this 24-week trial, reduction of neutrophil serine protease activity with brensocatib in patients with bronchiectasis was associated with improvements in bronchiectasis clinical outcomes. (Funded by Insmed; WILLOW ClinicalTrials.gov number, NCT03218917.).

Topics & Keywords

Cystic Fibrosis Research Advances Tracheal and airway disorders Neonatal Respiratory Health Research

Publication Details

Published in: New England Journal of Medicine

Volume 383, Issue 22, pp. 2127-2137

DOI: 10.1056/nejmoa2021713

Field-Weighted Citation Impact: 20.38

Command Palette

Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis

Authors

Abstract

Topics & Keywords

Publication Details